| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.6 | 1.7 |
| Net income | -56.9 | -43.8 |
| EPS (diluted, $ a share) | $-0.64 | $-0.57 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -3.7% |
|---|
10-Q filed with the SEC, NASDAQ: CGON. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CG Oncology, Inc.: key numbers
- Share price
- $84.78Close, Nov 16
- Market cap
- $7.57B
- Shares outstanding
- 89.32MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CG Oncology, Inc.
All →CG Oncology Clinical Trial Data
CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint, showing a 68% reduction in the risk of recurrence (hazard ratio of 0.32) compared to the control arm, with no Grade 3 or higher treatment-related adverse events reported.
CG Oncology Financial Results
CG Oncology reported third quarter 2026 financial results, highlighting a cash position of $984.5 million which is expected to fund operations through 2029. The company is approaching several clinical milestones, including anticipated Phase 3 topline data for PIVOT-006 in November 2026 and the completion of its BLA submission for BCG-unresponsive NMIBC in Q4 2026.
- Term
- Q3 2026
“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders.”
Arthur Kuan, Chairman, President & Chief Executive Officer
CG Oncology Director Leonard E. Post Sells $62.1K of Stock
Leonard E. Post, Director, sold 1,000 shares of CG Oncology, Inc. at $61.65 to $62.48 a share (average $62.06) in 2 transactions, worth $62.1K in total on Oct 15, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $62.1K
- Shares
- 1,000
- Average price
- $62.06
- Role
- Director
- Holding change
- -100.0%
- Trade date
- Oct 15, 2026